SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-517191"
 

Sökning: id:"swepub:oai:DiVA.org:uu-517191" > p53 stabilisation p...

p53 stabilisation potentiates [177Lu]Lu-DOTATATE treatment in neuroblastoma xenografts

Berglund, Hanna (författare)
Uppsala universitet,Cancerprecisionsmedicin
Lundsten Salomonsson, Sara (författare)
Uppsala universitet,Cancerprecisionsmedicin,Ridgeview Instruments AB, SE-752 38, Uppsala, Sweden
Mohajershojai, Tabassom (författare)
Uppsala universitet,Cancerprecisionsmedicin
visa fler...
Ferrer Gago, Fernando Jose (författare)
Lane, David P. (författare)
Uppsala universitet,Institutionen för immunologi, genetik och patologi,p53Lab, Agency for Science Technology and Research (A*STAR), Singapore, 138648, Singapore; Department of Microbiology, Tumour and Cell Biology, Karolinska Institute, SE-171 65, Solna, Sweden
Nestor, Marika, 1976- (författare)
Uppsala universitet,Cancerprecisionsmedicin
visa färre...
 (creator_code:org_t)
2023
2023
Engelska.
Ingår i: European Journal of Nuclear Medicine and Molecular Imaging. - : Springer. - 1619-7070 .- 1619-7089.
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • PurposeMolecular radiotherapy is a treatment modality that is highly suitable for targeting micrometastases and [177Lu]Lu-DOTATATE is currently being explored as a potential novel treatment option for high-risk neuroblastoma. p53 is a key player in the proapoptotic signalling in response to radiation-induced DNA damage and is therefore a potential target for radiosensitisation.MethodsThis study investigated the use of the p53 stabilising peptide VIP116 and [177Lu]Lu-DOTATATE, either alone or in combination, for treatment of neuroblastoma tumour xenografts in mice. Initially, the uptake of [177Lu]Lu-DOTATATE in the tumours was confirmed, and the efficacy of VIP116 as a monotherapy was evaluated. Subsequently, mice with neuroblastoma tumour xenografts were treated with placebo, VIP116, [177Lu]Lu-DOTATATE or a combination of both agents.ResultsThe results demonstrated that monotherapy with either VIP116 or [177Lu]Lu-DOTATATE significantly prolonged median survival compared to the placebo group (90 and 96.5 days vs. 50.5 days, respectively). Notably, the combination treatment further improved median survival to over 120 days. Furthermore, the combination group exhibited the highest percentage of complete remission, corresponding to a twofold increase compared to the placebo group. Importantly, none of the treatments induced significant nephrotoxicity. Additionally, the therapies affected various molecular targets involved in critical processes such as apoptosis, hypoxia and angiogenesis.ConclusionIn conclusion, the combination of VIP116 and [177Lu]Lu-DOTATATE presents a promising novel treatment approach for neuroblastoma. These findings hold potential to advance research efforts towards a potential cure for this vulnerable patient population.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Radiologi och bildbehandling (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Radiology, Nuclear Medicine and Medical Imaging (hsv//eng)
MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

Neuroblastoma
Molecular radiotherapy
p53
[177Lu]Lu-DOTATATE
Radiosensitisation

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy